Hans Petter Eikesdal
Overview
Explore the profile of Hans Petter Eikesdal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
283
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pedersen C, Cao M, Fleischer T, Rye M, Knappskog S, Eikesdal H, et al.
Breast Cancer Res
. 2022 Jun;
24(1):43.
PMID: 35751095
Background: Locally advanced breast cancer is a heterogeneous disease with respect to response to neoadjuvant chemotherapy (NACT) and survival. It is currently not possible to accurately predict who will benefit...
2.
Bertelsen B, Kellmann R, Viste K, Bjornevik A, Eikesdal H, Lonning P, et al.
J Endocr Soc
. 2020 Jun;
4(6):bvaa047.
PMID: 32500111
Background: Current analytical routine methods lack the sensitivity to monitor plasma estrogen levels in breast cancer patients treated with aromatase inhibitors. Such monitoring is warranted for premenopausal patients treated with...
3.
Andreassen M, Goa P, Sjobakk T, Hedayati R, Eikesdal H, Deng C, et al.
MAGMA
. 2019 Oct;
33(2):329-330.
PMID: 31664580
The original version of this article unfortunately contained a mistake in Fig. 6.
4.
Andreassen M, Goa P, Sjobakk T, Hedayati R, Eikesdal H, Deng C, et al.
MAGMA
. 2019 Sep;
33(2):317-328.
PMID: 31562584
Objectives: To investigate the reliability of simultaneous positron emission tomography and magnetic resonance imaging (PET/MRI)-derived biomarkers using semi-automated Gaussian mixture model (GMM) segmentation on PET images, against conventional manual tumor...
5.
Ottestad L, Fronth L, Rajendiran S, Hege Aksnes L, Eikesdal H, Store Blix E, et al.
Acta Oncol
. 2019 Feb;
58(3):385-387.
PMID: 30798641
No abstract available.
6.
Eikesdal H, Becker L, Teng Y, Kizu A, Carstens J, Kanasaki K, et al.
Mol Cancer Res
. 2018 Jun;
16(10):1568-1578.
PMID: 29934328
Deregulated transforming growth factor-β (TGFβ) signaling is a common feature of many epithelial cancers. Deletion of in fibroblast specific protein-1 (FSP1)-positive stromal cells induces squamous cell carcinoma in the murine...
7.
Yndestad S, Austreid E, Skaftnesmo K, Lonning P, Eikesdal H
Mol Cancer Res
. 2017 Oct;
16(1):78-89.
PMID: 29021233
Transcripts derived from the function as decoys to adsorb miRNAs targeting the tumor suppressor for degradation, and upregulation is known to inhibit growth in preclinical cancer models. Here, 3'UTR transduction...
8.
Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng P, Lonning P, et al.
Breast Cancer Res Treat
. 2017 Feb;
163(1):177-190.
PMID: 28213783
Purpose: PTEN is an important tumor suppressor in breast cancer. Here, we examined the prognostic and predictive value of PTEN and PTEN pseudogene (PTENP1) gene expression in patients with locally...
9.
Kim J, Correa de Sampaio P, Lundy D, Peng Q, Evans K, Sugimoto H, et al.
JCI Insight
. 2016 Dec;
1(21):e90733.
PMID: 28018977
Angiogenesis and co-optive vascular remodeling are prerequisites of solid tumor growth. Vascular heterogeneity, notably perivascular composition, may play a critical role in determining the rate of cancer progression. The contribution...
10.
Samdal Steinskog E, Sagstad S, Wagner M, Karlsen T, Yang N, Markhus C, et al.
Oncotarget
. 2016 Jun;
7(29):45789-45802.
PMID: 27329584
Increased lymphangiogenesis is a common feature of cancer development and progression, yet the influence of impaired lymphangiogenesis on tumor growth is elusive. C3HBA breast cancer and KHT-1 sarcoma cell lines...